Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy

Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the HER2 activity. Though, the main resistance to trastuzumab has...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cellular physiology Jg. 235; H. 4; S. 3142 - 3156
Hauptverfasser: Derakhshani, Afshin, Rezaei, Zohreh, Safarpour, Hossein, Sabri, Morteza, Mir, Atefeh, Sanati, Mohammad Amin, Vahidian, Fatemeh, Gholamiyan Moghadam, Ali, Aghadoukht, Ali, Hajiasgharzadeh, Khalil, Baradaran, Behzad
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Wiley Subscription Services, Inc 01.04.2020
Schlagworte:
Antineoplastic Agents - pharmacology
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Combination therapy
drug resistance
Drug Resistance, Neoplasm - drug effects
Epidermal growth factor
ErbB-2 protein
Growth factors
HER2 positive
Humans
Immunotherapy
Lapatinib - therapeutic use
Monoclonal antibodies
Receptor, ErbB-2 - drug effects
Targeted cancer therapy
Trastuzumab
Trastuzumab - therapeutic use
trastuzumab
HER2 positive
breast cancer
drug resistance
ISSN:0021-9541, 1097-4652, 1097-4652
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the HER2 activity. Though, the main resistance to trastuzumab has challenged the use of this drug in the management of HER2‐positive BC. Therefore, the determination of resistance mechanisms and the incorporation of new agents may lead to the development of a better blockade of the HER family receptor signaling. During the last few years, some therapeutic drugs have been developed for treating patients with trastuzumab‐resistant HER2‐positive BC that have more effective influences in the management of this condition. In this regard, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab‐resistant HER2‐positive BC subjects. Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. During the last few years, some therapeutic drugs have been developed for treating patients with trastuzumab‐resistant HER2‐positive BC that have more effective influences in the management of this condition. So, the present study aimed at reviewing the mechanisms of trastuzumab resistance and the innovative therapies that have been investigated in trastuzumab‐resistant HER2‐positive BC subjects.
Bibliographie:Afshin Derakhshani and Zohreh Rezaei contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0021-9541
1097-4652
1097-4652
DOI:10.1002/jcp.29216